The intranasal delivery route has generated considerable interest in the past couple of years, with numerous studies demonstrating promising results in improving the delivery of therapeutic vaccines. However, the rapidly growing cost of the overall development and manufacturing can be challenging, particularly for emerging biotech companies. To provide high-quality vaccine products, the formulations and delivery approaches need to be considered in designing new vaccines to ensure efficient induction of the innate and adaptive immune responses. In addition, manufacturing facilities need to be upgraded and expanded to scale the production to meet the potential rising of global demand for intranasal vaccines. In this webinar, experts will share insights into intranasal vaccine formulation development and discuss the current state of the art in intranasal vaccine production from development to commercial scale. In addition, a detailed discussion on the challenges and opportunities of intranasal approaches will be presented including the importance of device selection in determining product performance.
Key learning objectives:
- Describe the key factors that determine the success of an intranasal vaccine formulation
- Describe key manufacturing capabilities of intranasal vaccines
- Define the impact of key device characteristics on the delivery of liquid and powder based intranasal vaccines
Prof. Zhengrong Cui
Professor, College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery
The University of Texas, Austin
Zhengrong Cui is a Professor at The University of Texas at Austin (UT Austin), College of Pharmacy and a member of the LIVESTRONG Cancer Institutes at UT Austin Dell Medical School. He has over twenty years of research experience in pharmaceutical formulation development and drug and vaccine delivery. He has published extensively in his fields of expertise and is an inventor on several patents and patent applications. He holds a Ph.D. in pharmaceutical sciences from the University of Kentucky and completed his postdoctoral training at the University of Pittsburgh.
Director, Innovation and Partnerships – Nasal Delivery
Mark Ignaczak joined Catalent in 2021, bringing to his new role an extensive background in nasal spray product development and commercialization. Since 2004 he has worked in the pharmaceutical industry and since 2007 his career has focused on nasal spray products. He has contributed to around 75 nasal programs in varying stages within their project life cycles, ultimately launching more than 10 New Drug Applications (NDAs); some are considered first of their kind, best in class therapies. Throughout his career, Ignacak has fulfilled various roles within bioprocessing engineering, product development, supply chain and all aspects of nasal delivery program management and strategy.
Ignacak holds a bachelor’s in bio-chemical engineering from Rutgers University, New Brunswick, New Jersey.
Director, Business Development
Nektaria Karavas is the Director of Business Development for Nasal Vaccines, Antivirals and Immuno-stimulants at Aptar Pharma. Ms Karavas joined Aptar Pharma in 2004 and has held various commercial roles executing long-term strategy within key customer and global accounts in North America.
Date: Wednesday, June 29, 2022
Time: 11am ET / 4pm GMT / 5pm CET
Duration: 1 Hour